ELF3 and cancer: Importantly, mutations within the conserved ETS domain in EHF and ELF3 abolish the ability of these proteins to inhibit EMT, and this subsequently promotes tumor growth and invasion in vivo, leading to a dominant negative fashion on EMT and cancer cell differentiation in vivo (Sakamoto et al., 2021).